SRR5088815
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- INFLAMMATORY_RESPONSE+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- ANGIOGENESIS+0.300
- G2M_CHECKPOINT+0.300
Top 10 suppressed
- BILE_ACID_METABOLISM-0.200
- CHOLESTEROL_HOMEOSTASIS-0.100
- FATTY_ACID_METABOLISM-0.100
- HYPOXIA-0.100
- KRAS_SIGNALING_DN-0.100
- OXIDATIVE_PHOSPHORYLATION-0.100
- PEROXISOME-0.100
- ADIPOGENESIS+0.000
- ANDROGEN_RESPONSE+0.000
- DNA_REPAIR+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030627_D1.RNA-Seq | EPN | Supratentorial EPN | 0.895 |
| 2 | SRR1516055 | — | — | 0.877 |
| 3 | MNG256 | — | — | 0.874 |
| 4 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.874 |
| 5 | 20050099.TNBC | — | D | 0.870 |
| 6 | TCGA-FD-A3B7-01A-31R-A20F-07 | — | — | 0.867 |
| 7 | SRR29022839 | — | A | 0.867 |
| 8 | TCGA-56-8201-01A-11R-2247-07 | — | cohortA1 | 0.866 |
| 9 | SRR1516056 | — | — | 0.863 |
| 10 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |